Search results
Patients with chronic lung disease who live farther from a hospital found to have poorer survival...
Medical Xpress· 5 days agoIt is estimated that 32,500 people in the U.K. are living with idiopathic pulmonary fibrosis (IPF), a chronic progressive scarring lung disease which makes ...
'I'm a GP - you should never ignore this unusual sign on your hands'
Daily Express· 3 days agoWhen it comes to illnesses and health conditions many of the symptoms we experience will appear in...
Veracyte Core Tests Maintain Growth as Firm Prepares to Shift Resources to Newest Acquisitions
GenomeWeb News· 7 days agoVeracyte CEO Marc Stapley said during a call discussing the firm's first quarter financial results that the company views the new MRD technology, which it brought...
Insmed Incorporated (NASDAQ:INSM) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 4 days agoInsmed Incorporated (NASDAQ:INSM) Q1 2024 Earnings Call Transcript May 9, 2024 Insmed Incorporated...
Veracyte (NASDAQ:VCYT) Price Target Lowered to $27.00 at Needham & Company LLC
ETF DAILY NEWS· 6 days agoVeracyte (NASDAQ:VCYT – Free Report) had its target price trimmed by Needham & Company LLC from $33.00 to $27.00 in a research report report published on Wednesday morning, Benzinga reports.
Earnings call: Liquidia Corporation eyes FDA nod for YUTREPIA By Investing.com
Investing.com· 12 hours agoLiquidia Corporation (LQDA) reported its financial results for the first quarter of 2024 and...
Insmed (INSM) Beats on Q1 Earnings, Posts Upbeat Pipeline Updates
Zacks· 5 days agoInsmed (INSM) Q1 earnings beat estimates while sales miss the mark. Management posts positive data readouts from mid-stage studies on its experimental inhalation powder in PH-ILD and PAH indications.
Liquidia (LQDA) Scheduled to Post Earnings on Tuesday
ETF DAILY NEWS· 3 days agoLiquidia (NASDAQ:LQDA – Get Free Report) will post its quarterly earnings results before the market opens on Tuesday, May 14th. Analysts expect the company to announce earnings of ($0.32) per ...
Insmed stock target raised on positive trial results By Investing.com
Investing.com· 6 days agoOn Thursday, Morgan Stanley (NYSE:MS) showed a positive stance on Insmed (NASDAQ:INSM) Incorporated...
Minghui Pharmaceutical to Present the Phase I/II Study of MHB088C (B7-H3 ADC) for the Treatment of...
WTNH-TV New Haven· 7 days agoMinghui Pharmaceutical, Inc., a late-stage clinical biopharmaceutical company focused on autoimmune ...